Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PRMT7 CRISPR/Cas9 KO Plasmid (h): sc-417516
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PRMT7 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PRMT7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PRMT7 Antibody (E-9): sc-376077
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRMT7 CRISPR/Cas9 KO Plasmid (h) | sc-417516 | 20 µg | $397.00 |
Overview
PRMT7 encodes a type III protein arginine methyltransferase that catalyzes monomethylation of arginine residues on histones and non-histone substrates, shaping chromatin accessibility and protein–protein interactions. Through regulation of epigenetic programs, PRMT7 influences transcriptional control, cell-cycle progression, DNA damage responses, and differentiation-associated gene expression. PRMT7 activity intersects with broader arginine methylation networks and can modulate signaling outputs linked to stress adaptation and metabolic remodeling. Dysregulated PRMT7 expression or function has been associated with altered proliferation and lineage plasticity in cancer-relevant contexts, supporting its study in oncogenic epigenetics and transcriptional dependency models.
PRMT7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PRMT7 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PRMT7 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PRMT7 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PRMT7 protein expression.
This CRISPR knockout system enables efficient generation of PRMT7-deficient cell models for investigation of PRMT7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PRMT7 exon(s) critical for PRMT7 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PRMT7 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PRMT7 CRISPR/Cas9 KO Plasmid (h) and PRMT7 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PRMT7 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PRMT7 HDR Plasmid (h) and PRMT7 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PRMT7 homology arms to support homology-directed repair at defined PRMT7 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.